Background-Although drug-eluting stents have become a mainstay of percutaneous coronary intervention, information about drug-eluting stents outcomes in elderly patients is limited. Data from the paclitaxel-eluting stent (PES) trials and registries were pooled to assess PES benefits relative to advancing patient age, including comparison with bare-metal stents. Methods and Results-Data from 5 randomized trials (2271 patients with PES, 1397 patients with bare-metal stents) and from 2 postmarket registries (7492 patients with PES) were pooled separately. Each dataset was stratified into age groups: Ͻ60, 60 to 70, and Ͼ70 years. At baseline, patients aged Ͼ70 years in both datasets had significantly more adverse characteristics than younger patients. Through 5 years, trial data showed that patients aged Ͼ70 years had higher death rates, but comparable rates of myocardial infarction, stent thrombosis, and target lesion revascularization with younger patients. Compared with patients with bare-metal stents, patients with PES aged Ͼ70 years had comparable rates of death, myocardial infarction, and stent thrombosis but a significantly lower target lesion revascularization rate (22.2 versus 10.2, PϽ0.001). These findings were echoed in the registry data through 2 years that showed that PES patients aged Ͼ70 years had significantly higher death rates, but lower myocardial infarction, stent thrombosis, and target lesion revascularization rates, compared with younger patients. Although the mortality rates of patients aged Ͼ70 years were higher than those of younger patients, they were comparable with those of age-and gender-matched norms in the general population. Conclusions-This analysis of almost 10 000 patients demonstrated that percutaneous coronary intervention with PES is a safe and an effective treatment option that should not be withheld based on age. (Circ Cardiovasc Intervent. 2009; 2:178-187.)
T he elderly represent the fastest growing segment of the US population with currently Ϸ31 million adults aged 65 and older. Because age-related physiological changes predispose to coronary artery disease, 1 the number of elderly patients with coronary artery disease considered for revascularization will likely increase. Over the past 5 years, drugeluting stents (DES) have become a standard for percutaneous coronary intervention (PCI) because of their superior reduction of angiographic and clinical restenosis. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, the outcomes of DES in elderly patients who are fundamentally at higher risk because of increased prevalence of comorbid conditions as well as more complex and extensive atherosclerosis remain poorly studied. In the absence of age-specific data, some physicians empirically avoid DES in elderly patients, potentially depriving them of what may be a more beneficial treatment alternative.
Clinical Perspective on p 187
To address this gap in knowledge, we pooled 2271 patients receiving paclitaxel-eluting stents (PES) in randomized clinical trials and also separately pooled 7492 patients receiving PES in 2 "real-world" registries to study the relationship of safety and efficacy of PES with advancing age. We also studied 1397 patients with bare-metal stents (BMS; Boston Scientific Corporation, Natick, Mass) from the randomized trials to assess any differences in outcomes by stent type. Patients were divided into 3 groups: Ͻ60, 60 to 70, and Ͼ70 years of age. The impact of age on short-and long-term outcomes was compared among the 3 groups. The impact of age (continuous variable) as an independent predictor of outcomes was also assessed by multivariable modeling, and the annualized hazard rates (HRs) for adverse outcomes were assessed by deciles of age, in the trial and registry data.
Methods

Study Description
Data from the TAXUS pivotal trials and the ATLAS trial were pooled. The TAXUS I, II, IV, and V are prospective, multicenter, randomized, double-blind, controlled trials wherein increasingly complex patients with a single de novo lesion in a native coronary artery were randomized to receive either a paclitaxel-eluting TAXUS slow-release stent or an otherwise identical BMS. 2, 7, 8, 11 Follow-up was available through 5 years for the TAXUS I, II, and IV trials and through 4 years for the TAXUS V trial. The ATLAS trial is a prospective single-arm trial of the next generation TAXUS Liberté stent (Boston Scientific Corporation, Natick, Mass) 14 with follow-up available through 3 years.
Data from the ARRIVE 1 and 2 registries were pooled and analyzed separately from the randomized trials. The ARRIVE registries are 2-phase postmarket registries undertaken to study TAXUS Express 2 stent system usage in routine clinical practice through 2 years. 15
Definitions
All major adverse cardiac events were adjudicated by an independent clinical events committee. Death was defined as all-cause mortality. Myocardial infarction (MI) was defined as either the development of Numbers are % (n/N) or meanϮSD (n). P values for continuous variables were from ANOVA and for categorical variables were calculated by 2 test. ACC indicates American College of Cardiology; AHA, American Heart Association; CABG, coronary artery bypass graft; CHF, congestive heart failure; CVA, cerebrovascular accident; DS, diameter stenosis; MI, myocardial infarction; MLD, minimum lumen diameter; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; QCA, quantitative coronary angiography; RVD, reference vessel diameter; TIA, transient ischemic attack. pathological Q waves lasting at least 0.04 second in at least 2 contiguous leads with an elevated creatine kinase MB fraction level or, in the absence of Q waves, an elevation of creatine phosphokinase levels to greater than twice the upper limit of normal with an elevated creatine kinase MB level. Stent thrombosis (ST) data adjudicated by the Academic Research Consortium "definite or probable" definition were used in the present analysis. 16 Target lesion revascularization (TLR) was defined as repeat revascularization by either PCI or coronary artery bypass grafting (CABG) for ischemia with angiographic restenosis of at least 50% of the luminal diameter anywhere within the stent or the 5-mm borders proximal or distal to the stent.
Statistical Methods
All statistical analyses were performed by the biostatisticians at Boston Scientific Corporation. Potential bias was minimized by performing the analysis according to the intent-to-treat principle by including all patients randomized in the pooled trials and all patients receiving the TAXUS stent in the pooled registries. Second, the age-strata analysis was performed according to the age data collected at index procedure.
For continuous variables, comparison between the groups was performed with the ANOVA test. Time-to-event data were calculated and displayed as Kaplan-Meier estimates with comparison between groups by the log-rank test. Statistical significance was set at PϽ0.05. Annualized HRs were calculated for every year after the index procedure by using the person-year method. The approximate Poisson method was used to calculate the 95% CIs. HR differences between groups were calculated using the log-rank test with significance set at PϽ0.05.
Multivariate analyses were used to determine predictors of allcause death, MI, ST, and TLR using the Cox regression model. Variables included in the model for the trials were age, congestive heart failure, diabetes requiring medication, hyperlipidemia, previous CABG, calcification, reference vessel diameter, prior MI, minimum lumen diameter, unstable angina, left anterior descending artery versus nonleft anterior descending artery lesion location, multiple study stents, treatment group (TAXUS Express versus TAXUS Liberté), total occlusion, female gender, and lesion length. For the registries, the variables included age, congestive heart failure, diabetes requiring medication, left main stenting, prior MI, diabetes requiring insulin, cardiogenic shock, graft stenting, hypertension, lesion length Ͼ28 mm, female gender, hyperlipidemia, multiple planned stents, in-stent restenosis, lesion length, total occlusion, left anterior descending artery, reference vessel diameter, smoking, bifurcation, multiple lesions treated, reference vessel diameter Յ2.5 mm, percent diameter stenosis, and baseline acute MI.
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Randomized Trials
A total of 2797 patients were enrolled in the TAXUS I, II (slow-release arm), IV, and V trials between October 2000 and June 2003. Of these, 1400 patients were randomized to PES and 1397 patients to BMS. The 1400 patients who received PES were pooled with 871 patients from the ATLAS trial. Of the total 2271 pooled patients, 910 were Ͻ60 years, 785 were 60 to 70 years, and 576 were Ͼ70 years old. Of the 1397 patients with BMS, 593 were Ͻ60 years, 469 were 60 to 70 years, and 335 were Ͼ70 years old.
Baseline Characteristics
As shown in Table 1 , elderly patients (Ͼ70 years old) were significantly more likely to be female and to have more adverse baseline clinical comorbid conditions, including significantly higher incidences of congestive heart failure, prior CABG, hypertension, peripheral vascular disease (PVD), renal disease, and prior cerebrovascular accident, or transient ischemic attacks. They had lower body weight, significantly more B2/C lesions, and slightly smaller reference vessel diameter than the younger cohorts.
In-Hospital Outcomes
In-hospital outcomes of death, MI, TLR, and ST were comparable in all groups. In-hospital mortality was 0.0%, 0.0%, and 0.2% for patients aged Ͻ60, 60 to 70, and Ͼ70 years, respectively. However, there was a small (Ϸ6 hours) but statistically significant increase in the length of stay for patients aged Ͼ70 years (Ͻ60 years, 1.28Ϯ1.41 days; 60 to 70 years, 1.25Ϯ0.84 days; Ͼ70 years, 1.47Ϯ1.67 days; Pϭ0.007). Table 2 demonstrates that patients aged Ͼ70 years had significantly higher mortality in each time interval through 5 years. The HRs of MI, ST, and TLR remained constant and did not differ among the 3 groups in any time interval.
Safety and Efficacy End Points
Although the mortality was higher in patients aged Ͼ70 years in each time interval, their mortality risk remained near or below age-and gender-matched norms for the general population derived from the Social Security Database. The expected 1-year mortality rates for the general population were 0.61%, 1.82%, and 4.12%, whereas the actual observed rates were 0.78%, 1.03%, and 4.11% for patients aged Ͻ60, 60 to 70, and Ͼ70 years, respectively. Figure 1 shows Kaplan-Meier estimates representing 5-year cumulative rates of death, MI, ST, and TLR. The rate of all-cause death was significantly higher in patients aged Ͼ70 years (Ͻ60 years, 4.3%; 60 to 70 years, 8.7%; and Ͼ70 years, 18.3%; PϽ0.001). However, the rates of MI, ST, TVR (not shown), and TLR were comparable among all groups. Importantly, the increased mortality of patients aged Ͼ70 years was not linked to PES use ( Figure 2 ), given comparable rates of all-cause death, MI, and ST for patients aged Ͼ70 years treated with BMS or PES. The PES-treated patients did, however, show a significant reduction in the rate of TLR compared with patients with BMS (Ͻ60 years, 22.3% versus 13.1%, relative reduction 41%; 60 to 70 years, 18.6% versus 11.7%, relative reduction 37%; and Ͼ70 years, 22.2% versus 10.2%, relative reduction 54%; PϽ0.001 in all cases). Table 3 shows multivariate predictors of all-cause death, MI, ST, and TLR. Although advanced age was an independent predictor of all-cause death, it was not a predictor of MI and ST and actually significantly predicted reduced TLR. No interaction effect was observed for the combination of stent type (PES and BMS) and age on all-cause death.
Multivariate Predictors of 5-Year Clinical Outcomes
Registries
Between February 2004 and October 2005, 2487 and 5005 patients were enrolled in the ARRIVE 1 and ARRIVE 2 registries, respectively. Of these 7492 pooled patients receiving TAXUS stents, 2684 were Ͻ60 years, 2336 were 60 to 70 years, and 2472 were Ͼ70 years old.
Baseline Characteristics
As shown in Table 4 , patients aged Ͼ70 years were significantly more likely to be female, and medically complex, with significantly more multivessel disease, left main disease, as well as severe lesion calcification, tortuosity, and B2/C lesions compared with the younger cohorts.
In-Hospital Outcomes
Although in-hospital death remained low, it increased significantly with age (Ͻ60 years, 0.1%; 60 to 70 years, 0.5%; Ͼ70 years, 0.8%; Pϭ0.002). In-hospital outcomes of MI, TLR, and ST were comparable in all groups, with a small (Ϸ9 hours) but statistically significant increase in the length of stay for patients aged Ͼ70 years (Ͻ60 years, 1.57Ϯ1.83 days; 60 to 70 years, 1.56Ϯ2.43 days; Ͼ70 years, 1.93Ϯ2.61 days; PϽ0.001).
Safety and Efficacy End Points
As shown in Table 5 , patients aged Ͼ70 years had significantly higher mortality in each time interval through 2 years, but significantly lower HRs for MI, ST, and TLR. However, unlike the trial patients, the actual annualized mortality rates in the registry patients were actually slightly higher than those of age-and gender-matched general population in all age groups, particularly in patients aged Ͻ60 years. The expected 1-year mortality rates for the general population were 0.61%, 1.83%, and 4.81%, whereas the actual observed rates in the registry patients were 1.96%, 2.93%, and 5.95% for patients aged Ͻ60, 60 to 70, and Ͼ70 years, respectively. Figure 3 shows Kaplan-Meier estimates representing 2-year cumulative rates of death, MI, ST, and TLR. The rate of all-cause death was significantly higher in patients aged Ͼ70 years (Ͻ60 years, 3.1%; 60 to 70 years, 6.0% years; Ͼ70 years, 10.5%; PϽ0.001), but the rates of MI, ST, TVR (not shown), and TLR were significantly lower in patients aged Ͼ70 years. Table 6 shows multivariate predictors of all-cause death, MI, ST, and TLR. Although advanced age was an independent predictor of all cause-death, it was not a predictor of MI, and it actually significantly predicted reduced ST, and TLR in this complex registry population.
Multivariate Predictors of 2-Year Clinical Outcomes
An Integrated Perspective
The annualized HRs for death, MI, ST, and TLR were calculated for TAXUS-treated patients by deciles of age, separately for the randomized trials (through 5 years) and the registries (through 2 years; Figure 4 ). In both datasets, the significant increase in all-cause annual mortality with age is significant and greater for each age range in the medically more complex registry patients. There were trends toward reduced annual risk for MI and ST in older patients, partic-ularly in the registry cohort, and the age-related reduction in TLR was highly significant (PϽ0.001 by ANOVA).
Discussion
This analysis of almost 10 000 cumulative patients who received PES demonstrated that age Ͼ70 years had significantly more comorbid conditions and baseline risk factors, yet had comparable short-and long-term stent-related outcomes to younger patients. Furthermore, inclusion of a higher-risk registry dataset shows that these findings are potentially generalizable to today's expanding elderly PCI candidates.
Although the all-cause death was significantly higher in the elderly patients, with age being an independent predictor of annual mortality risk in both the trial and registry datasets, this age-related increase in mortality in the randomized trials was comparable for patients treated with PES and BMS and therefore not attributable to PES per se. Moreover, the annual mortality rates of elderly patients with single de novo lesions treated with PES in the clinical trials remained near age-and gender-matched norms for the general population. Even in the more complex registry patients, the observed annual mortality rates were only slightly higher than the general population for all age groups, with a smaller relative increase in the elderly patients (5.95% versus 4.81%; relative increase 23.7%) than in patients aged 60 to 70 years (2.93% versus 1.83%; relative increase 60.1%) or Ͻ60 years (1.96% versus 0.63%; relative increase 211%), likely reflecting the greater relative clinical penalty of premature clinical coronary disease. Our observed mortality rates for patients aged Ն80 years are generally aligned with those in a recent study by Vlaar et al, 17 which reported a 12-month mortality of 8.9%.
In comparison with younger patients, elderly patients are more often treated noninvasively even when their clinical status would otherwise support revascularization. The Trial of Invasive Versus Medical Therapy in Elderly Patients With Numbers are % (n/N) or meanϮSD (n). P values for continuous variables were from ANOVA and for categorical variables were calculated by 2 test. ACC indicates American College of Cardiology; AHA, American Heart Association; CABG, coronary artery bypass graft; CHF, congestive heart failure; CVA, cerebrovascular accident; DS, diameter stenosis; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; QCA, quantitative coronary angiography; RVD, reference vessel diameter; TIA, transient ischemic attack. 
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Chronic Angina (TIME) compared medical strategy with PCI in patients aged Ն75 years. 18 At 4-year follow-up, patients assigned to PCI had similar mortality (28%), but less frequent late revascularizations, more symptomatic benefit, fewer follow-up events, and decreased need for anti-ischemic medications than the medical group. 19 The Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease study showed better long-term outcomes of Ͼ6000 elderly patients undergoing revascularization (CABG and PCI) compared with those treated with medications alone and supported appropriate use of revascularization in elderly patients. 20 When elderly patients undergo CABG, however, the risk of mortality and morbidity increase with age, particularly among women, and there is a high prevalence and persistence of cognitive decline after CABG. 21, 22 These factors, combined with the rapid recovery after PCI, would tend to favor PCI over CABG in elderly patients indicated for revascularization, if there were not similar age-related degradation in postprocedure outcome. The introduction of BMS dramatically improved the success of balloon angioplasty by reducing emergency bypass surgery, restenosis, and the need for subsequent revascularization. Octogenarians treated with Palmaz-Schatz stents were reported to have more acute complications, a higher in-hospital and increased late mortality than younger patients. 23 Although literature regarding DES is limited, Gro-enveld et al 24 reported that elderly Medicare beneficiaries receiving DES had significant reductions in revascularization, hospitalization for acute MI, and mortality than patients receiving BMS. These findings are supported by our study, which demonstrated a 54% reduction in TLR rate in patients aged Ͼ70 years receiving PES, with no associated increase in death, MI, or ST compared with patients randomized to receive an otherwise identical BMS.
The unique contribution of our study is the compelling demonstration of the preserved safety and efficacy of PES treatment in patients aged Ͼ70 years compared with those aged 60 to 70 years and Ͻ60 years. In a large patient population drawn from clinical trials and registries, we observed that advanced age was associated with the expected increase in the annual mortality but that this treatment did not significantly increase that mortality compared with patients treated with BMS or with the age-matched general population. Furthermore, we demonstrated that patients aged Ͼ70 years had comparable or lower rates of subsequent MI and ST than younger patients, and a significantly lower rate of repeat revascularization than younger patients. This may be indicative of less aggressive atherosclerotic disease in the elderly, compared with younger patients (particularly those presenting with premature coronary artery disease at the age of Ͻ60 years). Overall, however, these data show no reason to withhold PCI with PES on the basis of advanced age alone in 
Study Limitations
This analysis is a post hoc study of prospective trials. Although adverse events were monitored and independently adjudicated, this is inherently an observational study. There is considerable heterogeneity among the age-derived groups, in terms of greater baseline comorbid conditions, female gender, and increased lesion complexity in patients aged Ͼ70 years. Although multivariable models were used to determine the independent contribution of advanced age to outcome, there were certainly other unmeasured differences among the 3 age groups. This study reports the results of paclitaxel-eluting TAXUS stents, and extension to other types of DES should probably be done cautiously pending stent-specific results. Nor does it compare their performance with other therapeutic alternatives, such as medical therapy or CABG. The sample size of patients aged Ͼ70 years limited the separate evaluation of octogenarians and nonagerians. Finally, although this study demonstrates the short-and long-term efficacy of DES, it does not assess non-life-threatening bleeding risks associated with the long-term antiplatelet therapy. This prolonged medication requirement can become problematic for elderly patients because of their intrinsically higher bleeding risks, although the literature supports the premise that elderly persons can tolerate antiplatelet therapy with good clinical effects. 25 
Conclusions
This comprehensive study of the PES clinical trials and "real-world" registries demonstrates that PCI with PES is a safe and an effective treatment option in patients aged Ͼ70 years, with low rates of MI, ST, and TLR comparable with those of younger patients. Although patients aged Ͼ70 years have a higher annual death rate, this rate is comparable with those treated with BMS, as well as age-and gender-matched norms for the general population. Advanced age alone should not be taken as a contraindication to PCI using PES in elderly patients with compelling indications for revascularization, suitable coronary anatomy, and ability to undergo the procedure. ARC indicates Academic Research Consortium; CHF, congestive heart failure; LAD, left anterior descending; MI, myocardial infarction; RVD, reference vessel diameter; ST, stent thrombosis; TLR, target lesion revascularization.
*Age was forced into the model; a hazard ratio Ͻ1.0 indicates a trend for decreasing events with increasing age.
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Forman-Paclitaxel-Eluting Stent Outcomes in the Elderly Figure 4 . Annualized HR versus age plots through 5 years for patients receiving PES in the randomized trials (left); through 2 years for patients receiving PES in the registries (right) (P values by ANOVA).
